cox 189 has been researched along with ibuprofen in 15 studies
| Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) | Studies (ibuprofen) | Trials (ibuprofen) | Recent Studies (post-2010) (ibuprofen) |
|---|---|---|---|---|---|
| 163 | 49 | 47 | 10,245 | 1,781 | 4,267 |
| Protein | Taxonomy | cox 189 (IC50) | ibuprofen (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 2.9 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 1.1 | |
| Albumin | Bos taurus (cattle) | 3 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 4.0919 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 0.22 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.6273 | |
| Caspase-1 | Homo sapiens (human) | 7.2667 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 1.1 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.0687 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 1.3 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 10 | |
| Caspase-3 | Homo sapiens (human) | 7.2667 | |
| Caspase-4 | Homo sapiens (human) | 7.2667 | |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 1.1 | |
| Caspase-5 | Homo sapiens (human) | 7.2667 | |
| Caspase-9 | Homo sapiens (human) | 7.2667 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 1.1375 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 2.9 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 5 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.54 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 8 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 1.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fricke, JR; Jayawardene, S; Kellstein, D; Zelenakas, K | 1 |
| Gimona, A; Hawkey, C; Kivitz, AJ; Nayiager, S; Schimansky, T; Thurston, HJ | 1 |
| Ehrsam, E; Farkouh, M; Gitton, X; Hawkey, CJ; Huels, J; Richardson, P | 1 |
| Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P | 1 |
| Summerton, N | 1 |
| Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW | 1 |
| Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM | 1 |
| Hawkey, CJ; Krammer, G; Murphy, V; Rebuli, R; Richard, D; Stricker, K; Weinstein, WM | 1 |
| Krammer, G; Lheritier, K; Littlejohn, TW; MacDonald, TM; Rebuli, R; Reginster, JY; Richard, D | 1 |
| Chesebro, JH; Farkouh, ME; Gitton, X; Jeger, R; Kirshner, H; Krammer, G; Matchaba, P; Mellein, B; Ruland, S; Sallstig, P; Stricker, K; Verheugt, FW | 1 |
| Krammer, G; Lheritier, K; MacDonald, TM; Richard, D | 1 |
| Harirforoosh, S; Pettit, WL; Wyatt, JE | 1 |
2 review(s) available for cox 189 and ibuprofen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides | 2012 |
10 trial(s) available for cox 189 and ibuprofen
| Article | Year |
|---|---|
Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain.
Topics: Adolescent; Adult; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Ibuprofen; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pilot Projects; Tooth Extraction; Treatment Outcome | 2004 |
Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Humans; Ibuprofen; Middle Aged; Organic Chemicals; Peptic Ulcer; Treatment Outcome | 2004 |
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Health Status; Humans; Ibuprofen; Isoenzymes; Membrane Proteins; Middle Aged; Naproxen; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Prognosis; Prostaglandin-Endoperoxide Synthases; Risk Factors | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides | 2004 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis | 2007 |
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Duodenal Ulcer; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Risk Factors; Risk Reduction Behavior; Stomach Ulcer | 2007 |
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Statistics as Topic | 2008 |
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Hypertension; Ibuprofen; Middle Aged; Osteoarthritis; Treatment Outcome | 2008 |
A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Creatinine; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Pain Measurement | 2008 |
The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Ibuprofen; Male; Middle Aged; Osteoarthritis; Treatment Outcome | 2010 |
3 other study(ies) available for cox 189 and ibuprofen
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Evidence in practice--number 3: Cox 2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medicine; Humans; Ibuprofen; Middle Aged; Naproxen; Organic Chemicals; Osteoarthritis; Stomach Ulcer | 2004 |